| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3938 |
| Trial ID | NCT06492876 |
| Disease | Diabetic Macular Edema |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | FT-003 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Dose-escalation and Dose-expanded Phase I/II Clinical Study to Evaluate the Safety, and Efficacy of FT-003 in Subjects With DME |
| Year | 2024 |
| Country | China |
| Company sponsor | Frontera Therapeutics |
| Other ID(s) | FT003-CD101 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||
|
|||||||